ENANTA PHARMACEUTICALS, INC Income Taxes Receivable
ENANTA PHARMACEUTICALS, INC (ENTA) had Income Taxes Receivable of $19.00 thousand as of 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Balance Sheet › Assets
us-gaap:IncomeTaxReceivable · last filed 2026-05-13
- 2026-03-31: Income Taxes Receivable $19.00K.
- 2025-09-30: Income Taxes Receivable $0.00.
- 2025-06-30: Income Taxes Receivable $24.00K.
- 2025-03-31: Income Taxes Receivable $33.84M.
| Period end | Income Taxes Receivable |
|---|---|
| 2026-03-31 | $19.00K 10-Q · filed 2026-05-13 |
| 2025-09-30 | $0.00 10-Q · filed 2026-05-13 |
| 2025-06-30 | $24.00K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $33.84M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $32.44M 10-Q · filed 2025-02-12 |
| 2024-09-30 | $32.00M 10-K · filed 2025-11-19 |
| 2024-06-30 | $32.45M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $32.03M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $31.73M 10-Q · filed 2024-02-08 |
| 2023-09-30 | $31.00M 10-K · filed 2024-11-27 |
| 2023-06-30 | $25.92M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $28.77M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $28.70M 10-Q · filed 2023-02-08 |
| 2022-09-30 | $28.72M 10-K · filed 2023-11-22 |
| 2022-06-30 | $28.73M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $28.75M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $28.75M 10-Q · filed 2022-02-10 |
| 2021-09-30 | $37.26M 10-K · filed 2022-11-23 |
| 2021-06-30 | $30.57M 10-Q · filed 2021-08-09 |
| 2020-09-30 | $13.04M 10-K · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |